Trial Profile
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jan 2024
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SPRINT; SPRINT Stratum 1
- 03 Oct 2023 Results of 5 years of additional safety and efficacy data, published in the Neuro-Oncology
- 08 May 2023 According to AstraZeneca media release, Selumetinib has been approved in China for treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type I aged 3 years and above. The approval by the National Medical Products Administration (NMPA) in China was based on positive results from this study.
- 03 Apr 2023 According to an AstraZeneca media release, Health Canada has granted a Notice of Compliance (NOC) for KOSELUGO (selumetinib) for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Health Canada's authorization of KOSELUGO was based on positive results from this study.